Clinical trial · Observational
Relmacabtagene Autoleucel in Patients With LBCL
A Real World Study of Treatment of Relmacabtagene Autoleucel in Relapsed or Refractory Large B-Cell Lymphoma
NCT06142175CI-TRIAL-00075483unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate the efficacy and safety of Relmacabtagene autoleucel for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) in real-world
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Large B-cell Lymphoma | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Relmacabtagene Autoleucel | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Relmacabtagene Autoleucel
- description
- Relmacabtagene Autoleucel administered as a single IV infusion at a target dose of 1 x 10\^8 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells on Day1.
- interventionNames
- Biological: Relmacabtagene Autoleucel
Primary outcomes (1)
- measure
- ORR
- timeFrame
- 6 months
- description
- Percentage of participants with CR or PR
Secondary outcomes (5)
- measure
- CRR
- timeFrame
- 6 months
- description
- Complete response rate
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Adult patients with established r/r LBCL; 2. Patients already treated with commercially available Relmacabtagene Autoleucel Exclusion Criteria: No
References
Publications (0)
Data not yet available
No reference posted for this study.